Work Group Report: COVID-19: Unmasking Telemedicine

Hare, Nathan; Bansal, Priya; Bajowala, Sakina; Abramson, Stuart L.; Chervinskiy, Sheva K.; Corriel, Robert; Hauswirth, David W.; Kakumanu, Sujani; Mehta, Reena; Rashid, Quratulain; Rupp, Michael R.; Shih, Jennifer; Mosnaim, Giselle

doi:10.1016/j.jaip.2020.06.038

Cited by 67 publications

(70 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, the use of telemedicine has rapidly progressed since the onset of the Covid-19 pandemic in an effort to reduce unnecessary in person medical visits. 54 , 55 Due to this many allergy and immunology clinicians have had to rapidly incorporate telemedicine into their practices. 54 , 55 A recent meta-analysis found that both tele-case management and tele-consultation were effective telemedicine tools in improving asthma control and quality of life in adult patients.…”

Section: Should Treatment Guidelines Change During the Covid-19 Pandementioning

confidence: 99%

“… 54 , 55 Due to this many allergy and immunology clinicians have had to rapidly incorporate telemedicine into their practices. 54 , 55 A recent meta-analysis found that both tele-case management and tele-consultation were effective telemedicine tools in improving asthma control and quality of life in adult patients. 56 Additionally, telemedicine was shown to be non-inferior to in-person consultations for asthma treatment and management.…”

Section: Should Treatment Guidelines Change During the Covid-19 Pandementioning

confidence: 99%

“… 54 Clinicians should take into account individualized patient circumstances when choosing between in-person and telemedicine consultations for the diagnosis and treatment of asthma. 55 …”

Section: Should Treatment Guidelines Change During the Covid-19 Pandementioning

confidence: 99%

See 2 more Smart Citations

Asthma and COVID-19: What do we know now

Hughes-Visentin

Paul

2020

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

The COVID-19 pandemic has presented challenges in symptomology identification, diagnosis, management and follow-up in common respiratory diseases, and in particular asthma. Research is rapidly ongoing to try and understand how the SARS-CoV-2 virus affects individuals with asthma, as well as, how underlying asthma affects Covid-19 risk, symptomology and prognosis. In light of this unique medical challenge, clinicians are faced with case-by-case based decisions to implement or continue current asthma therapy. This review will discuss the current literature regarding asthma and COVID-19 based on best available evidence at this time (See box 1).

show abstract

Section: Should Treatment Guidelines Change During the Covid-19 Pandementioning

confidence: 99%

Section: Should Treatment Guidelines Change During the Covid-19 Pandementioning

confidence: 99%

See 1 more Smart Citation

Asthma and COVID-19: What do we know now

Hughes-Visentin

Paul

2020

Clin Med Insights Circ Respir Pulm Med

View full text Add to dashboard Cite

show abstract

“…. Considering this last aspect, the SARS-CoV-2 crisis has obliged physicians to adopt telemedicine in a very accelerated way to maintain essential care for patients with epilepsy during the pandemic [11,12]. On the other hand, the discussion about SUDEP and the possibility of the occurrence of a greater number of cases of premature death among individuals with epilepsy has not been receiving special attention during application of telehealth.…”

mentioning

confidence: 99%

“…In this context, although the medical team's first reaction was to limit access to clinics and neurological centers to preserve patients with epilepsy from being infected [ 10 ], some interesting proposals regarding healthcare facilities logistics, medical procedures and treatment (ensuring a regular supply of antiepileptic drugs), and telemedicine have also been discussed among various epileptologists operating in different regions of the world [ 4 , [7] , [8] , [9] , [10] , [11] ]. Considering this last aspect, the SARS-CoV-2 crisis has obliged physicians to adopt telemedicine in a very accelerated way to maintain essential care for patients with epilepsy during the pandemic [ 11 , 12 ]. On the other hand, the discussion about SUDEP and the possibility of the occurrence of a greater number of cases of premature death among individuals with epilepsy has not been receiving special attention during application of telehealth.…”

mentioning

confidence: 99%

Doctors race to understand epilepsy in the time of COVID-19

Almeida

Cysneiros

Scorza

et al. 2020

Epilepsy & Behavior

View full text Add to dashboard Cite

We enjoyed reading the recent article entitled, "Epilepsy self-management during a pandemic: Experiences of people with epilepsy" by Miller and colleagues published in your esteemed journal [1]. Although these data are extremely interesting, we have to be very careful when discussing them. Firstly, it is evident to all scientists that the new coronavirus (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) infection has become a worldwide pandemic and a global health threat that mobilized healthcare workers in all disciplines [2]. Despite ongoing advances, careful clinical, diagnostic, and epidemiological studies are still necessary to acknowledge manifestations and the burden of neurological disease caused by SARS-CoV-2 [3], including epilepsy [4]. Because of the clinical importance of these considerations, we would like to add some thoughts that may open the debate about the possible increase in cases of sudden unexpected death in epilepsy (SUDEP) during this current serious pandemic. In fact, the SARS-CoV-2 pandemic that hit the central Chinese city of Wuhan in late December 2019 and subsequently spread rapidly to all provinces of China and all countries worldwide has had a negative impact on global public health [5]. Severe acute respiratory syndrome coronavirus 2 is characterized by a high contagiousness. In this sense, in 85% of cases, it causes subclinical or mild disease, but compared with flu, it easily causes more respiratory complications (e.g., severe pneumonia [ground glass opacities] and interstitial pneumonia) in 10-15% of cases [5]. Moreover, 5% of infected patients require intensive care unit (ICU) admission [5]. During these catastrophic scenarios, lethality is estimated at around 0.7-7% [5,6]. On the basis of knowledge of other coronaviruses, the contagiousness of SARS-CoV-2 is higher, but the mortality is decidedly lower compared with the severe acute respiratory syndrome (SARS) of 2002 and the Middle East respiratory syndrome (MERS) of 2012, both of them related with higher mortality (9.5% and 34.4%, respectively) [5,6]. Furthermore, it has been suggested that for patients with severe or critical illness, besides the respiratory supportive treatment, a more careful assessment and the treatment of various affected organs are important [6]. Thus, the neurological implications of SARS-CoV-2 infection have received special attention [3], and neuroscientists have established consensus recommendations on how to provide the best possible care for people with epilepsy during the novel coronavirus 2019 era [1,7-10]. In this context, although the medical team's first reaction was to limit access to clinics and neurological centers to preserve patients with epilepsy from being infected [10], some interesting proposals regarding healthcare facilities logistics, medical procedures and treatment (ensuring a regular supply of antiepileptic drugs), and telemedicine have also been discussed among various epileptologists operating in different regions of the world [4,7

show abstract

Allergic patients during the COVID‐19 pandemic—Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey

Alvaro‐Lozano

Sandoval‐Ruballos

Giovannini

et al. 2022

Clinical & Translational All

View full text Add to dashboard Cite

Background:The COVID-19 pandemic has affected health care systems unexpectedly. However, data focusing on practical considerations experienced by health care professionals (HCPs) providing care to allergic patients is scarce.This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

show abstract

Work Group Report: COVID-19: Unmasking Telemedicine

Cited by 67 publications

References 27 publications

Asthma and COVID-19: What do we know now

Asthma and COVID-19: What do we know now

Doctors race to understand epilepsy in the time of COVID-19

Allergic patients during the COVID‐19 pandemic—Clinical practical considerations: An European Academy of Allergy and Clinical Immunology survey

Contact Info

Product

Resources

About